The ideal characteristics of antiepileptic therapy: An overview of old and new AEDs

Acta Neurologica Scandinavica

Volumn 107, Issue 2, 2003, Pages 87-95

  Steinhoff, Bernard J ^a,e   Hirsch, E ^b   Mutani, R ^c   Nakken, K O ^d  

^a Epilepsy Center Kork   (Germany)

^b HÔPITAL CIVIL   (France)

^c UNIVERSITY OF TURIN   (Italy)

^d Statens senter for epilepsi   (Norway)

^e Epilepsy Centre Kork   (Germany)

Author keywords

Antiepileptic drugs; Epilepsy

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EPILEPSY; GERIATRIC DISORDER; GERIATRICS; GESTATIONAL AGE; GINGIVA DISEASE; HIRSUTISM; HUMAN; HYPERPLASIA; LEARNING DISORDER; POPULATION RESEARCH; PROPHYLAXIS; REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO; WEIGHT GAIN;

ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY; HUMANS; TREATMENT OUTCOME;

EID: 0037291832     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.01311.x     Document Type: Review

References (46)

1. JALLON P. The problem of intractability: the continuing need for new medical therapies in epilepsy. Epilepsia 1997;38(Suppl. 9):S37-S42.
2. COMMISSION ON CLASSIfiCATION and TERMINOLOGY OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY. Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 1989;26:268-78.
3. ENGEL J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force Classification and Terminology. Epilepsia 2001;42:796-803.
4. SCHACHTER SC. Antiepileptic drug therapy: General treatment principles and application for special patient populations. Epilepsia 1999;40(Suppl. 9):S20-S25.
5. BEGHI E, PERUCCA E. The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research. Drugs 1995;49:680-94.
6. MATTSON RH. Drug treatment of uncontrolled seizures. Epilepsy Res 1992;5(Suppl. 9):29-35.
7. KWAN P, BRODIE MJ. Early identification of refractory epilepsv. N Engl J Med 2000;342:314-9.
8. ARNOLD S, SCHAUG G, NIEMANN H et al. Topography of interictal glucose hypometabolism in unilateral mesiotemporal epilepsy. Neurology 1996;46:1422-30.
9. PETROFF OA, ROTHMAN DL, BEHAR KL, MATTSON RH. Low brain GABA level is associated with poor seizure control. Ann Neurol 1996;40:908-11.
10. ZIEMANN U, STEINHOFF BJ, TERGAU F, PAULUS W. Transcranial magnetic stimulation: its current role in epilepsy research. Epilepsy Res 1998;30:11-30.
11. NAMER IJ, BOLO NR, SELLAL F et al. Combined measurements of hippocampal N-acetyl-aspartate and T2 relaxation time in the evaluation of mesial temporal lobe epilepsy: correlation with clinical severity and memory performances. Epilepsia 1999;40:1424-32.
12. ASCONAPÉ J, DIEDRICH A, DELLABADIA J. Myoclonus associated with the use of gabapentin. Epilepsia 2000;41:479-81.
13. GUERRINI R, DRAVET C, GENTON P, BELMONTE A, KAMINSKA A, DULAC O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12.
14. ECKARDT KM, STEINHOFF BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 1998;39:671-4.
15. GENTON P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22:75-80.
16. SOZUER DT, ATAKLI D, ATAY T, BAYBAS S, ARPACI B. Evaluation of various antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia 1996;37(Suppl. 4):77.
17. DULAC O, PLOUIN P, SHEWMON A. Myoclonus and epilepsy in childhood: 1996 Royaumont meeting. Elpilepsy Res 1998;30:91-106.
18. MURPHY K, DELANTY N. Primary generalized epilepsies. Curr Treat Options Neurol 2000;2:527-42.
19. NANBA Y, MAEGAKI Y. Epileptic negative myoclonus induced by carbamazepine in a child with BECTS. Benign childhood epilepsy with centrotemporal spikes. Pediatr Neurol 1999;21:664-7.
20. ELDRIDGE R, IIVANAINEN M, STERN R, KOERBER T, WILDER BJ. 'Baltic' myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983;2:838-42.
21. MARCIANI MG, MASCHIO M, SPANEDDA F, IANI C, GIGLI GL, BERNARDI G. Development of myoclonus in patients with partial epilepsy during treatment with vigabatrin: an electroencephalographic study. Acta Neurol Scand 1995;91:1-5.
22. NEUFELD MY, VISHNEVSKA S. Vigabatrin and multifocal myoclonus in adults with partial seizures. Clin Neuropharmacol 1995;18:280-3.
23. GARCIA PASTOR A, GARCIA-ZARZA E, PERAITA ADRADOS R. Acute encephalopathy and myoclonic status induced by vigabatrin monotherapy. Neurologia 2000;15:370-4.
24. MATSUO F. Lamotrigine Epilepsia 1999;40(Suppl. 5):S30-S36.
25. GATTI G, BARTOLI A, MARCHISELLI R, MICHELUCCI R, TASSINARI CA, PISANI F. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993;36:603-6.
26. SENNOUNE S, BONNETON J, GENTON P, DRAVET C, ROGER J, MESDJIAN E. Interactions between vigabatrin and standard anitepileptic drugs. Epilepsia 1994;35:65.
27. PATSALOS PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
28. BRODIE MJ, YUEN AWC & THE 105 STUDY GROUP. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res 1997;26:423-32.
29. PISANI F, OTERI G, RUSSO MF, DI PERRI R, PERUCCA E, RICHENS A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-6.
30. STOLAREK I, BLACKLAW J, FORREST G, BRODIE MJ. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994;57:921-4.
31. STEPHEN LJ, SILLS GJ, BRODIE MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998;351:958-9.
32. CRAMER J, VACHON L, DESFORGES C, SUSSMAN NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-7.
33. TOMSON T, JOHANNESSEN SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000;55:697-705.
34. PERUCCA E. Pharmacological problems in the management of epilepsy in children. Seizure 1995;4:139-43.
35. So EL. Update on epilepsy. Med Clin North Am 1993;77:203-14.
36. MEIERKORD H, GRÜNING F, GUTSCHMIDT U et al. Sodium bromide: effects on different patterns of epileptiform activity, extracellular pH changes and GABAergic inhibition. Naunyn Schmiedebergs Arch Pharmacol 2000;361:25-32.
37. MUTANI R, CANTELLO R, GIANELLI M et al. and cellular targets for anti-epileptic drugs. London: John Libbey, 1997;131-40.
38. MATTSON RH, PETROFF O, ROTHMAN D, BEHAR K. Vigabatrin: effects on human brain GABA levels using nuclear magnetic resonance spectroscopy. Epilepsia 1994;35(Suppl. 5):S29-S32.
39. PETROFF OA, ROTHMAN DL, BEHAR KL, MATTSON RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 1996;46:1459-63.
40. PETROFF OA, ROTHMAN DL, BEHAR KL, COLLINS TL, MATTSON RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996;47:1567-71.
41. ZIEMANN U, LÖNNECKER S, STEINHOFF BJ, PAULUS W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996;40:367-78.
42. STEINHOFF BJ. New measurements of efficacy and toxicity. In: STEFAN H, KRÄMER G, MAMOLI B, eds. Challenge epilepsy - new antiepileptic drugs. Berlin Vienna: Blackwell, 1998;151-63.
43. WIESER HG, RUSS W, BOESIGER P, et al. Examination of the profile and changes of brain metabolites in epilepsy patients suffering from complex partial seizures of mesial temporal lobe origin before and after treatment with vigabatrin by means of proton magnetic resonance spectroscopy. In: STEFAN H, KRÄMER G, MAMOLI B, eds. Challenge epilepsy - new antiepileptic drugs. Berlin Vienna: Blackwell, 1998;229-35.
44. LÖSCHER W, HÖNACK D, RUNDFELDT C. Anti-epileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284:474-9.
45. YLINEN A, SALMENPERA T, MUMFORD JP, RIEKKINEN PJ. Long-term treatment with vigabatrin - 10 years of clinical experience. Seizure 1999;8:181-3.
46. SUTULA TP, HERMANN B. Progression in mesial temporal lobe epilepsy (Editorial). Ann Neurol 1999;45:553-6.